- Home
- Capebel DT 500 mg Tablet
Capebel DT 500 mg Tablet Substitute
Capebel DT 500 mg Tablet Substitute
All Substitutes & Brand Comparisons
RX
Capegard 500 Tablet 10's
Cipla Ltd
₹839
(₹75.51 per unit)
62% CHEAPERRX
Capibine 500 mg Tablet 10's
Dr Reddy's Laboratories Ltd
₹1073.5
(₹88.03 per unit)
56% CHEAPERRX
Capnat 500 mg Tablet 10's
Natco Pharma Ltd
₹1044
(₹93.96 per unit)
53% CHEAPERRX
Capitab 500 mg Tablet 10's
Aureate Healthcare
₹1050
(₹94.5 per unit)
53% CHEAPERRX
Citabin 500 mg Tablet 10's
United Biotech Pvt Ltd
₹1054.5
(₹94.91 per unit)
53% CHEAPERRX
Benzicap-500 Tablet 10's
Admac Pharma Ltd
₹1183.5
(₹97.05 per unit)
52% CHEAPERRX
Tabine Tablet 10's
Cellgen Biopharma
₹1054.5
(₹100.18 per unit)
50% CHEAPERRX
Bdocin 500 Tablet 10's
BDR Pharmaceuticals Internationals Pvt Ltd
₹1155.5
(₹104.0 per unit)
48% CHEAPERRX
Capetero-500 Tablet 10's
Hetero Healthcare Pvt Ltd
₹1183
(₹106.47 per unit)
47% CHEAPERRX
Capsy 500 Tablet 10's
Intas Pharmaceuticals Ltd
₹1183.5
(₹106.52 per unit)
47% CHEAPERRX
Cacit 500 Tablet 10's
Jitron Pvt Ltd
₹1183.5
(₹106.52 per unit)
47% CHEAPERRX
Capecite-500 Tablet 8's
Abbott India Ltd
₹963
(₹108.34 per unit)
46% CHEAPERRX
Xeloda 500 mg Tablet 10's
₹1262
(₹111.06 per unit)
45% CHEAPERRX
Capeaim-500 Tablet 10's
Aimcad Biotech Pvt Ltd
₹1262
(₹111.06 per unit)
45% CHEAPERRX
ATUBRI 500MG TABLET
Pfizer Ltd
₹1800
(₹162.0 per unit)
20% CHEAPER
Verified Ingredients and Effects
Composition:
CAPECITABINE-500MG
Uses:
Breast cancer, stomach, rectal and colon cancer
Medicinal Benefits:
Capebel DT 500 mg Tablet belongs to the group of anti-cancer medicines. It contains Capecitabine which is cytotoxic (causes cell death). It is used to treat cancer of the colon, breast and stomach. When taken, it gets converted into 5-fluorouracil (chemical), which hampers the synthesis of genetic materials (DNA) in the cancer cells, thereby interfering with their growth. As a result, the growth of cancer cells is slowed down, and eventually, they are killed.
FAQs
Capebel DT 500 mg Tablet interferes with the growth of the cancer cells' genetic material (DNA). This slows the growth of cancer cells and eventually kills them.
Capebel DT 500 mg Tablet can make your skin more sensitive to the harmful effects of sunlight. Hence it is advised to wear protective clothing while using Capebel DT 500 mg Tablet . It is recommended to avoid tanning booths and sunlamps.
Yes, Capebel DT 500 mg Tablet may change the results of blood tests and other laboratory tests. Inform the person doing the tests that you are taking Capebel DT 500 mg Tablet as regular monitoring of liver and kidney functions tests, electrolyte levels and blood cells is required.
Capebel DT 500 mg Tablet might affect fertility (ability to have children) in both men and women. You may not be able to become pregnant or father a child after treatment with Capebel DT 500 mg Tablet . However, it is essential to talk to your doctor before starting treatment with Capebel DT 500 mg Tablet if you think you may want to have a baby in the future.
Yes, Capebel DT 500 mg Tablet commonly affects the hair by making it thin, which further causes hair loss. However, it is not very common. Hair reduction possibly happens due to the estrogen-lowering effect of Capebel DT 500 mg Tablet . These effects are not long-lasting and may return after some time. If it matters to you, then consult your doctor for further advice.
Capebel DT 500 mg Tablet may cause osteoporosis (bone thinning) due to the reduction of estrogen in the body. Regular bone density tests may help you monitor osteoporosis. Contact your doctor if you observe any sign of tendon pain or swelling while taking Capebel DT 500 mg Tablet .
Your doctor will decide the number of treatment cycles and the frequency of Capebel DT 500 mg Tablet to be taken, depending on the type and stage of the cancer being treated.
No, it is advised not to use these two medicines at the same time as they may cause severe drug reactions. Maintain a gap of at least four weeks between the last dose of brivudine and the first dose of Capebel DT 500 mg Tablet .
